Reunion Neuroscience Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2 study of RE104, a novel serotonergic psychedelic compound, for the treatment of postpartum depression (PPD). The Phase 2 study, the RECONNECT Trial, is a multicenter, randomized, double-blind, parallel-group, active-dose placebo-controlled study, which will evaluate the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with PPD. The study is expected to begin in fourth quarter 2023 with a targeted data readout in late 2024.
1st Jan change | Capi. | |
---|---|---|
+25.73% | 661B | |
+26.74% | 566B | |
-6.51% | 352B | |
+20.44% | 332B | |
+3.25% | 283B | |
+13.47% | 231B | |
+4.74% | 200B | |
-9.49% | 195B | |
-5.08% | 145B |